Abstract
In 25 outpatients taking digoxin for chronic atrial fibrillation (established for at least six months) a prospective study identified only one case in which rapid availability of the results of a plasma digoxin assay altered the dose which had already been selected on the basis of simple clinical assessment. No patient received more than 375 micrograms digoxin per day and none showed clinical evidence of toxicity even though seven had renal impairment. Six other patients had poorly controlled ventricular rates requiring larger doses of digoxin, but even in these patients the dose could be selected on clinical grounds alone. Despite the availability of a very rapid fluorescence polarisation immunoassay for digoxin, simple but careful clinical monitoring is an adequate basis for the selection of a suitable dose in most patients taking digoxin for atrial fibrillation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ferreri L. F., Raisys V. A., Opheim K. E. Analysis of digoxin concentrations in serum by fluorescence polarization immunoassay: an evaluation. J Anal Toxicol. 1984 May-Jun;8(3):138–140. doi: 10.1093/jat/8.3.138. [DOI] [PubMed] [Google Scholar]
- Marty J., Fullinfaw R., Tuckett R., Trembath P., King J. Evaluation of the provision of rapid drug plasma assays in an outpatient anticonvulsant clinic. Ther Drug Monit. 1981;3(3):253–258. doi: 10.1097/00007691-198103000-00005. [DOI] [PubMed] [Google Scholar]
- Morgan D. B. The appropriate use of diagnostic services. Part II. The case for fewer measurements of the plasma sodium concentration: costs and gains. Health Trends. 1985 Feb;17(1):1–3. [PubMed] [Google Scholar]
- Smith T. W., Haber E. Digitalis. I. N Engl J Med. 1973 Nov 1;289(18):945–952. doi: 10.1056/NEJM197311012891805. [DOI] [PubMed] [Google Scholar]